Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BDSI to roll out Onsolis in Canada
Onsolis, which will be marketed as Breakyl, is indicated for the management of pain in opioid tolerant, adult patients with cancer. BDSI’s Onsolis is expected to be marketed
Onsolis, which will be marketed as Breakyl, is indicated for the management of pain in opioid tolerant, adult patients with cancer. BDSI’s Onsolis is expected to be marketed
With this acquisition, Frutarom will strengthen its activity and market share in developing markets in Eastern Europe, Africa and Asia, and will strengthen its current product supply chain
As per the terms of the deal, Autifony will issue 850,000 A ordinary shares to GSK in exchange for a number of pre-candidate voltage-gated ion channel modulator compounds
The agreement replaces a promotion agreement that the companies signed in July 2008. The tie up allows Santarus to record revenue from Glumetza sales in the US effective
The grant is expected to fund two thirds of the development cost of the project. Within this subsidized project, Activus will develop ophthalmic solutions that would differ from
Moviprep is a laxative solution that increases the amount of water in the intestinal tract to stimulate bowel movements. This medication also contains potassium, sodium and other minerals
The program aims to advance the understanding of retinal vascular diseases which cause vision loss, including wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema
The new data showed that a single injection of ocriplasmin resolved VMA and the visual symptoms associated with it in 29.8% of VMT patients, compared with 7.7% of
Sansoz has filed the case with a hope that the court will find that its generic version of Novo Nordisk’s diabetes drug Prandin (repaglinide) is non-infringing, Bloomberg reported.
Tolnaftate, the active ingredient of Tolnaftate-D, is already approved as a treatment of jock itch, athlete’s foot and ringworm. Apricus Biosciences wholly owned subsidiary NexMed’s Tolnaftate-D uses NexACT